H.C. Wainwright analyst Douglas Tsao downgraded Outlook Therapeutics (OTLK) with a price target of $1, down from $3. The firm is “disappointed “that the FDA issued a complete response letter for ONS-5010 in wet age-related macular degeneration. It downgraded Outlook after removing all future U.S. revenues for ONS-5010 from its valuation.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook CRL ‘a significant setback,’ doesn’t mean end for Lytenava, says Chardan
- Outlook Therapeutics downgraded to Neutral from Buy at Guggenheim
- Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
- Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
- Outlook Therapeutics Reports Q3 2025 Earnings and Milestones